Currently, there is limited and conflicting evidence supporting the use of C-reactive protein (CRP) [12,16,17,18] or Procalcitonin (PCT) [6,11,19,20,21] for diagnosing ICU-acquired infections in COVID-19 patients, usually limited to the evaluation of their potential role in diagnosing ventilator-associated pneumonia. This evidence concerns the gene CRP and ventilator-associated pneumonia.